Radium 223 is a type of internal radiotherapy treatment. It is used to target metastatic Ca prostate with symptomatic bone metastasis. Compared to placebo, it improves survival with HR 0.7. Usually the cost varies among different hospitals and depends on facilities charges. The treatment is also available in some HA hospitals.